Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, 10x Genomics Inc’s stock clocked out at $14.99, up 5.53% from its previous closing price of $14.20. In other words, the price has increased by $5.53 from its previous closing price. On the day, 3.02 million shares were traded. TXG stock price reached its highest trading level at $15.06 during the session, while it also had its lowest trading level at $13.82.
Ratios:
To gain a deeper understanding of TXG’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 66.21. For the most recent quarter (mrq), Quick Ratio is recorded 4.12 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on September 03, 2024, initiated with a Outperform rating and assigned the stock a target price of $35.
On July 22, 2024, Jefferies Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $24.
JP Morgan Downgraded its Overweight to Neutral on July 18, 2024, whereas the target price for the stock was revised from $40 to $20.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 22 ’24 when Saxonov Serge sold 6,693 shares for $13.69 per share. The transaction valued at 91,612 led to the insider holds 872,574 shares of the business.
Hindson Benjamin J. sold 5,807 shares of TXG for $79,485 on Nov 22 ’24. The insider now owns 339,897 shares after completing the transaction at $13.69 per share. On Nov 22 ’24, another insider, Hindson Benjamin J., who serves as the Officer of the company, bought 5,734 shares for $13.32 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TXG now has a Market Capitalization of 1814599424 and an Enterprise Value of 1502323200. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.74 while its Price-to-Book (P/B) ratio in mrq is 2.51. Its current Enterprise Value per Revenue stands at 2.386 whereas that against EBITDA is -11.147.
Stock Price History:
Over the past 52 weeks, TXG has reached a high of $57.90, while it has fallen to a 52-week low of $12.95. The 50-Day Moving Average of the stock is -4.61%, while the 200-Day Moving Average is calculated to be -34.45%.
Shares Statistics:
It appears that TXG traded 2.05M shares on average per day over the past three months and 1633560 shares per day over the past ten days. A total of 106.98M shares are outstanding, with a floating share count of 99.75M. Insiders hold about 17.60% of the company’s shares, while institutions hold 78.78% stake in the company. Shares short for TXG as of 1732838400 were 6904875 with a Short Ratio of 3.37, compared to 1730332800 on 7608141. Therefore, it implies a Short% of Shares Outstanding of 6904875 and a Short% of Float of 7.470000000000001.
Earnings Estimates
The market rating of 10x Genomics Inc (TXG) is currently shaped by the ongoing analysis conducted by 3.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.19 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.28 and -$1.41 for the fiscal current year, implying an average EPS of -$0.66. EPS for the following year is -$0.61, with 3.0 analysts recommending between -$0.26 and -$1.28.
Revenue Estimates
In the current quarter, 15 analysts expect revenue to total $153.51M. It ranges from a high estimate of $155.1M to a low estimate of $151.49M. As of the current estimate, 10x Genomics Inc’s year-ago sales were $183.98MFor the next quarter, 15 analysts are estimating revenue of $142.26M. There is a high estimate of $153.7M for the next quarter, whereas the lowest estimate is $136.78M.
A total of 16 analysts have provided revenue estimates for TXG’s current fiscal year. The highest revenue estimate was $600.9M, while the lowest revenue estimate was $597.26M, resulting in an average revenue estimate of $599.4M. In the same quarter a year ago, actual revenue was $618.73MBased on 16 analysts’ estimates, the company’s revenue will be $632.93M in the next fiscal year. The high estimate is $656.9M and the low estimate is $610.93M.
